Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy. (1st October 2019)
- Record Type:
- Journal Article
- Title:
- Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy. (1st October 2019)
- Main Title:
- Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy
- Authors:
- Harries, Iwan
Biglino, Giovanni
Baritussio, Anna
De Garate, Estefania
Dastidar, Amardeep
Plana, Juan Carlos
Bucciarelli-Ducci, Chiara - Abstract:
- Abstract: Background: Anthracycline cardiomyopathy contributes to the morbidity and mortality of cancer survivors but long-term data are lacking. This study sought to describe the phenotype of long-term anthracycline cardiomyopathy, the prevalence of myocardial fibrosis and its association with cardiac remodeling, systolic function and clinical outcomes. Methods and results: We undertook contrast-enhanced CMR in 81 cancer survivors at median 5 years after anthracycline (mean dose 279 SD 89 mg/m 2 ). Participants were aged 55 SD 14 years; 68% were female. Mean LVEF was impaired (49 SD 12%), driven by a pathological increase in iLVESV (47 SD 23 ml/m 2 ). 19% of participants exhibited LGE, which was associated with significant adverse left ventricular remodeling and reduced systolic function (iLVEDV: 102 SD 34 vs 83 SD 21 ml/m 2, p = 0.03; iLVESV 61 SD 32 vs 43 SD 20 ml/m 2, p = 0.03; LVEF: 43 SD 11 vs 50 SD 12%, p = 0.03). In subgroup analysis of 36 patients, 36% had elevated native T1 measurements, which was associated with significant adverse left ventricular remodeling (iLVEDV: 97 SD 22 vs 74 SD 19 ml/m 2, p = 0.002; iLVESV: 56 SD 22 vs 35 SD 15 ml/m 2, p = 0.005), reduced systolic function (LVEF 44 SD 13 vs 55 SD 9%, p = 0.01), and hospitalizations for heart failure (38% vs 9%, p = 0.03). Absolute native T1 measurements correlated significantly with iLVEDV (p ≤ 0.001, R 2 0.33), iLVESV (p < 0.001, R 2 0.36), LVEF (p < 0.001, R 2 0.35), LAVi (p = 0.04, R 2 0.12) and MAPSEAbstract: Background: Anthracycline cardiomyopathy contributes to the morbidity and mortality of cancer survivors but long-term data are lacking. This study sought to describe the phenotype of long-term anthracycline cardiomyopathy, the prevalence of myocardial fibrosis and its association with cardiac remodeling, systolic function and clinical outcomes. Methods and results: We undertook contrast-enhanced CMR in 81 cancer survivors at median 5 years after anthracycline (mean dose 279 SD 89 mg/m 2 ). Participants were aged 55 SD 14 years; 68% were female. Mean LVEF was impaired (49 SD 12%), driven by a pathological increase in iLVESV (47 SD 23 ml/m 2 ). 19% of participants exhibited LGE, which was associated with significant adverse left ventricular remodeling and reduced systolic function (iLVEDV: 102 SD 34 vs 83 SD 21 ml/m 2, p = 0.03; iLVESV 61 SD 32 vs 43 SD 20 ml/m 2, p = 0.03; LVEF: 43 SD 11 vs 50 SD 12%, p = 0.03). In subgroup analysis of 36 patients, 36% had elevated native T1 measurements, which was associated with significant adverse left ventricular remodeling (iLVEDV: 97 SD 22 vs 74 SD 19 ml/m 2, p = 0.002; iLVESV: 56 SD 22 vs 35 SD 15 ml/m 2, p = 0.005), reduced systolic function (LVEF 44 SD 13 vs 55 SD 9%, p = 0.01), and hospitalizations for heart failure (38% vs 9%, p = 0.03). Absolute native T1 measurements correlated significantly with iLVEDV (p ≤ 0.001, R 2 0.33), iLVESV (p < 0.001, R 2 0.36), LVEF (p < 0.001, R 2 0.35), LAVi (p = 0.04, R 2 0.12) and MAPSE (p = 0.02, R 2 0.14). Conclusions: Long-term anthracycline cardiomyopathy is characterized by pathologically increased iLVESV. Both LGE and elevated native T1 measurements were associated with significant adverse cardiac remodeling and reduced systolic function, and the latter with heart failure hospitalizations. Highlights: Increased LV end-systolic volume is typical of late anthracycline cardiomyopathy. LGE is associated with adverse LV remodeling and lower LVEF. Elevated native myocardial T1 is associated with adverse LV remodeling and lower LVEF. Native myocardial T1 correlates with LV volumes, EF, LAVi and MAPSE. … (more)
- Is Part Of:
- International journal of cardiology. Volume 292(2019)
- Journal:
- International journal of cardiology
- Issue:
- Volume 292(2019)
- Issue Display:
- Volume 292, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 292
- Issue:
- 2019
- Issue Sort Value:
- 2019-0292-2019-0000
- Page Start:
- 248
- Page End:
- 252
- Publication Date:
- 2019-10-01
- Subjects:
- Cardiology -- Periodicals
Electronic journals
616.12 - Journal URLs:
- http://www.clinicalkey.com/dura/browse/journalIssue/01675273 ↗
http://www.sciencedirect.com/science/journal/01675273 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijcard.2019.04.026 ↗
- Languages:
- English
- ISSNs:
- 0167-5273
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.158000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11163.xml